Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors

Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors

Background: Targeted therapy drugs, including imatinib, are used for inhibiting the marker oncoprotein of chronic myeloid leukemia — BCR-ABL tyrosine kinase. However, in some patients the drug resistance can emerge too rapidly and a previous treatment with chemotherapy drugs can lead to formation of...

Повний опис

Збережено в:
Бібліографічні деталі
Опубліковано в: :Experimental Oncology
Дата:2014
Автори: Zhaleiko, I.O., Perekhrestenko, T.P., Bilko, D.I., Dyagil, I.S., Bilko, N.M.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2014
Теми:
Original contributions
Онлайн доступ:https://nasplib.isofts.kiev.ua/handle/123456789/145345
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors / I.O. Zhaleiko, T.P. Perekhrestenko, D.I. Bilko, I.S. Dyagil, N.M. Bilko // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 112-116. — Бібліогр.: 19 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-145345
record_format dspace
spelling Zhaleiko, I.O.
Perekhrestenko, T.P.
Bilko, D.I.
Dyagil, I.S.
Bilko, N.M.
2019-01-20T18:07:56Z
2019-01-20T18:07:56Z
2014
Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors / I.O. Zhaleiko, T.P. Perekhrestenko, D.I. Bilko, I.S. Dyagil, N.M. Bilko // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 112-116. — Бібліогр.: 19 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145345
Background: Targeted therapy drugs, including imatinib, are used for inhibiting the marker oncoprotein of chronic myeloid leukemia — BCR-ABL tyrosine kinase. However, in some patients the drug resistance can emerge too rapidly and a previous treatment with chemotherapy drugs can lead to formation of resistance. Aim: To evaluate the influence of drugs that were used prior to the imatinib on the performance of the functional activity of bone marrow cells from chronic myeloid leukemia patients and their indivi­dual responses to therapy. Methods: Bone marrow aspirate from 57 patients, who were getting busulfan (19 patients) or hydroxycarbamide (38 patients) prior to imatinib was studied with cytogenetic and tissue culture methods in vitro. Results: Obtained data suggested that pretreatment with busulfan, regardless of duration, negatively affects the response to further therapy with imatinib. Instead, after using hydroxycarbamide as a previous therapy for six month, there was optimal response to imatinib. In those cases when duration of pretreatment with hydroxycarbamide was increased to a year or more, there was a suboptimal response and a resistance to imatinib therapy. In addition, there was a positive correlation between the number of cell aggregates (colonies and clusters) in semisolid agar and the duration of a prior treatment with hydroxycarbamide, if previous therapy did not exceed 20 months. With an increase of pretreatment terms to 21 months or more, such a correlation was not observed. Conclusions: These results suggest that chemotherapeutic agents (busulfan and hydroxycarbamide) may additionally contribute to the accumulation of mutations in the genome of leukemic cell clone affecting the behavior of these cells in vitro. Key Words: chronic myeloid leukemia, imatinib, pretreatment, hydroxycarbamide, busulfan, cell culture in vitro.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors
spellingShingle Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors
Zhaleiko, I.O.
Perekhrestenko, T.P.
Bilko, D.I.
Dyagil, I.S.
Bilko, N.M.
Original contributions
title_short Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors
title_full Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors
title_fullStr Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors
title_full_unstemmed Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors
title_sort determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in cml-patients treated with tyrosine kinase inhibitors
author Zhaleiko, I.O.
Perekhrestenko, T.P.
Bilko, D.I.
Dyagil, I.S.
Bilko, N.M.
author_facet Zhaleiko, I.O.
Perekhrestenko, T.P.
Bilko, D.I.
Dyagil, I.S.
Bilko, N.M.
topic Original contributions
topic_facet Original contributions
publishDate 2014
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Background: Targeted therapy drugs, including imatinib, are used for inhibiting the marker oncoprotein of chronic myeloid leukemia — BCR-ABL tyrosine kinase. However, in some patients the drug resistance can emerge too rapidly and a previous treatment with chemotherapy drugs can lead to formation of resistance. Aim: To evaluate the influence of drugs that were used prior to the imatinib on the performance of the functional activity of bone marrow cells from chronic myeloid leukemia patients and their indivi­dual responses to therapy. Methods: Bone marrow aspirate from 57 patients, who were getting busulfan (19 patients) or hydroxycarbamide (38 patients) prior to imatinib was studied with cytogenetic and tissue culture methods in vitro. Results: Obtained data suggested that pretreatment with busulfan, regardless of duration, negatively affects the response to further therapy with imatinib. Instead, after using hydroxycarbamide as a previous therapy for six month, there was optimal response to imatinib. In those cases when duration of pretreatment with hydroxycarbamide was increased to a year or more, there was a suboptimal response and a resistance to imatinib therapy. In addition, there was a positive correlation between the number of cell aggregates (colonies and clusters) in semisolid agar and the duration of a prior treatment with hydroxycarbamide, if previous therapy did not exceed 20 months. With an increase of pretreatment terms to 21 months or more, such a correlation was not observed. Conclusions: These results suggest that chemotherapeutic agents (busulfan and hydroxycarbamide) may additionally contribute to the accumulation of mutations in the genome of leukemic cell clone affecting the behavior of these cells in vitro. Key Words: chronic myeloid leukemia, imatinib, pretreatment, hydroxycarbamide, busulfan, cell culture in vitro.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/145345
citation_txt Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors / I.O. Zhaleiko, T.P. Perekhrestenko, D.I. Bilko, I.S. Dyagil, N.M. Bilko // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 112-116. — Бібліогр.: 19 назв. — англ.
work_keys_str_mv AT zhaleikoio determinationoftheoptimalchemotherapydrugspretreatmenttimethroughcultivationofhemopoieticcellsincmlpatientstreatedwithtyrosinekinaseinhibitors
AT perekhrestenkotp determinationoftheoptimalchemotherapydrugspretreatmenttimethroughcultivationofhemopoieticcellsincmlpatientstreatedwithtyrosinekinaseinhibitors
AT bilkodi determinationoftheoptimalchemotherapydrugspretreatmenttimethroughcultivationofhemopoieticcellsincmlpatientstreatedwithtyrosinekinaseinhibitors
AT dyagilis determinationoftheoptimalchemotherapydrugspretreatmenttimethroughcultivationofhemopoieticcellsincmlpatientstreatedwithtyrosinekinaseinhibitors
AT bilkonm determinationoftheoptimalchemotherapydrugspretreatmenttimethroughcultivationofhemopoieticcellsincmlpatientstreatedwithtyrosinekinaseinhibitors
first_indexed 2025-12-07T18:51:59Z
last_indexed 2025-12-07T18:51:59Z
_version_ 1850876645131419648

Схожі ресурси